1. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV- negative recipients with an anti-HBc-positive donor 
C. Cerva, L. Colagrossi, G. Maffongelli, R. Salpini, D. Di Carlo, V. Malagnino, A. Battisti, A. Ricciardi, M. Pollicita, A. Bianchi, A. Picardi, L. Cudillo, R. Cerretti, G. De Angelis, M. Cantonetti, M. Andreoni, C.F. Perno, W. Arcese, V. Svicher, L. Sarmati 
Clinical Microbiology and Infection 
Volume 22, Issue 11, Pages 946.e1-946.e8 (November 2016)
DOI: /j.cmi
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2. Fig. 1
Survival analysis by competing risk estimates of the cumulative probability of HBV reactivation. The cumulative probability of HBV reactivation was evaluated in the group of 59 patients 6 years from HSCT. Events of HBV reactivation, transplant-related mortality and death for haematological relapse were evaluated.
Clinical Microbiology and Infection  , 946.e1-946.e8DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions